Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media

Pediatric Infectious Disease Journal

Volumn 23, Issue 9, 2004, Pages 834-838

  Block, Stan L ^a   Busman, Todd A ^b   Paris, Maria M ^b   Bukofzer, Stanley ^b  

^a Kentucky Pediatric Research Institute   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Acute otitis media; Amoxicillin clavulanate; Cefdinir

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFDINIR; PNEUMOCOCCUS VACCINE; CEPHALOSPORIN DERIVATIVE;

ACCIDENT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPER DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OTITIS MEDIA; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; UNITED STATES; VOMITING; ACUTE DISEASE; CHILD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MICROBIOLOGY; PROBABILITY; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE DISEASE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; OTITIS MEDIA; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 6344240723     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000137574.28711.c4     Document Type: Article

References (17)

1. Bradley JS, Nelson JD. In: Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 15th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:28.
2. Block SL, Harrison CJ. In: Diagnosis and Management of Acute Otitis Media. 2nd ed. Caddo, OK: Professional Communications, Inc.; 2003:93.
3. Adler M, McDonal PJ, Trostmann U, et al. Comparative safety and efficacy of cefdinir vs. amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 2000;19:S166-S170.
4. Block S, McCarty JM, Hedrick JA, et al. Comparative safety and efficacy of cefdinir vs. amoxicillin/clavulanate for treatment of suppurative acute otitis media in children. Pediatr Infect Dis J. 2000;19:S159-S165.
5. Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J. 2001;20:1-5.
6. Block SL, Hedrick JA, Harrison CJ. Community-wide vaccination with heptavalent pneumococcal conjugate vaccine significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829-833.
7. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
8. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
9. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J. 1997;16:463-470.
10. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
11. American Academy of Pediatrics and American Academy of Family Physicians. Clinical practice guidelines: diagnosis and management of acute otitis media. Pediatrics. In press.
12. Marchant CD, Carlin SA, Johnson CE, et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the "Pollyanna phenomenon". J Pediatr. 1992;120:72-77.
13. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin-clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20:829-837.
14. Bottenfield GW, Burch DJ, Hedrick JA, Schaten R, Rowinski CA, Davies JT. Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin clavulanate (Augmentin) in the empiric treatment of pediatric otitis media caused by drug-resistant Streptococcus pneumoniae. Pediatr Infect Dis J. 1998;17:963-968.
15. Sader HS, Fritsche TR, Mutnick AH, Jones RN. Contemporary evaluation of in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn Microbiol Infect Dis. 2003;47:515-525.
16. Block SL, Hedrick JA, Kratzer J, Nemeth MA, Tack KJ. Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy. Pediatr Infect Dis J. 2000;19:S153-S158.
17. Powers JL, Gooch WM 3rd, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil, and azithromycin in pediatric patients. Pediatr Infect Dis J. 2000;19:S174-S180.